Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal, Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.

Amplitude Venture Capital

Alexandria Venture Investments is a strategic venture capital arm of Alexandria Real Estate Equities. Alexandria Venture Investments provides long-term strategic investment capital to innovative life science and technology entities developing breakthrough technologies and therapies.  Leveraging their experience and in-depth understanding of the life science and technology industries, their long-term relationships with leading investors, and their world-class scientific advisory network, they  are uniquely positioned to fund seed-, early-, and growth-stage companies.

Alexandria

MaRS Innovation (MI) is a commercialization engine that integrates, centralizes and accelerates time to market of the discovery and intellectual property assets from its 15 world-class research institutions.   MI’s discovery and innovation pipeline is derived from $1 billion in annual R&D funding. Created as a not-for-profit organization through the Government of Canada’s Center of Excellence for Commercialization and Research program (CECR), MI has raised $50 million from federal and provincial governments, member institutions and industry partners. MI’s vision is to transform the Toronto-based research enterprise into one of world’s most successful commercialization clusters.  Through detailed, market facing due diligence, MI identifies opportunities from Canada’s largest academic cluster for further development and commercialization through project management, intellectual property management, investment and technology development. By crossing the innovation gap, MI transforms these opportunities into successful high-value licensing transactions and financeable start-up companies.

Toronto Innovation Acceleration Partners

SickKids Foundation believe fighting for the health and wellbeing of children is one of the most powerful ways to improve society.    Right now, quantum advancements in scientific knowledge and technology – made possible by donors like you – present an unprecedented opportunity for SickKids. To be ready for the next round, they need to update their infrastructure so they can unleash the full potential of SickKids expert team.   They need to expand their reach, to extend their excellent standards of care to more children around the world. They need to elevate their research - it’s their best weapon in the fight against disease and congenital childhood conditions. And they must enrich the compassionate care they believe fosters the lifelong wellbeing of children and their families.    It’s a massive challenge, but one that has to be met. So we’re actively inspiring communities and individuals to take up the fight by investing in their Hospital, its mission, and the health and scientific advances your gifts make possible.

SickKids Foundation

FACIT is a commercialization venture firm that builds companies with entrepreneurs to accelerate oncology innovation, with a portfolio that has attracted over $850 million in investment to Ontario. Blending industry experience, capital and the unsurpassed clinician-scientist network of its strategic partner the Ontario Institute for Cancer Research (OICR), FACIT capitalizes on the province's investment in research and healthcare to the benefit of the local economy and patients worldwide.

FACIT

The Bill & Melinda Gates Foundation is a grant-making foundation that supports initiatives in education, world health and population, and community giving in the Pacific Northwest. In its local region, the foundation promotes strategies and programs that help low income families.The Bill & Melinda Gates Foundation was co-founded by Bill Gates and Melinda Gates in 2000 and is based in Seattle, Washington, with regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom. Its trustees are Bill and Melinda Gates, and Warren Buffett.

Bill & Melinda Gates Foundation

BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets. The company helps create and develop strong Canadian businesses through financing, consulting services and securitization, with a focus on small and medium-sized enterprises. BDC Venture Capital has been involved in venture capital since 1975 and has to date invested in more than 400 companies involved in the areas of Life Sciences, Telecommunications, Information Technology and Advanced Technologies.

BDC Venture Capital

Abrdn enables its clients to plan, save, and invest for their futures. Abrdn is operating across three vectors that reflect how their clients interact with them. Abrdn has the full ecosystem of capabilities to enable our clients to be better investors.

Abrdn

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.

Alexandria Venture Investments

Radiant Biotherapeutics

Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients.

Radiant Biotherapeutics is a biotechnology company developing a novel antibody platform called Multabody. Radiant is based on foundational science from The Hospital for Sick Children (SickKids) and the University of Toronto. The company's proprietary Multabody platform leverages both multivalency and multi-specificity to generate highly efficacious antibodies with superior potency compared to traditional antibody platforms. These Multabodies are designed to have 24 binding sites, claiming to have a stronger and more secure hold on targets compared to conventional antibodies with only two binding sites, allowing Multabodies to potentially address targets that traditional antibodies cannot effectively engage.

Radiant to Assess Multi-Valent, Multi-Specific Multabodies as Potential Treatments for HIV

Radiant BioTherapeutics — utilizing multabodies to transform antibody therapeutics

Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships

FACIT generates $1.5 billion in follow-on investment

FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Radiant Biotherapeutics Closes $35M Series A Financing

Radiant Biotherapeutics is a revolutionary biotechnology company developing a proprietary antibody platform called Multabody to generate highly potent and efficacious multi-valent, multi-specific therapeutic antibodies. The Multabody platform leverages avidity and multi-specificity simultaneously, enabling superior potency compared to traditional antibody platforms. These powerful Multabodies have the potential to deliver a new class of biologics capable of tackling complex diseases like cancer, autoimmune conditions, and infectious diseases that often have challenging targets and mechanisms.
Radiant's groundbreaking platform can generate mono-, bi-, and tri-specific Multabodies with the ability to target multiple binding areas of a disease target, overcoming limitations of existing therapies. The exceptional potency of Multabodies allows small drug amounts to effectively destroy circulating viral particles and viral reservoirs in immune cells. In December 2023, Radiant received a USD 2 million grant from the Bill & Melinda Gates Foundation to assess Multabodies as potential HIV treatments, aiming to eradicate the disease by eliminating latent viral stores.
Multabody production leverages standard antibody manufacturing processes, offering a flexible, modular, and scalable approach. Radiant is rapidly advancing its novel pipeline of Multabody therapeutics across multiple disease areas. In April 2023, the company emerged from stealth mode after raising an USD 8 million seed round led by Amplitude Ventures and securing two undisclosed pharma partnerships, validating the platform's broad scientific and clinical utility.

Radiant Biotherapeutics is a biotechnology company developing a novel antibody platform called Multabody. Radiant is based on foundational science from The Hospital for Sick Children (SickKids) and the University of Toronto. The company's proprietary Multabody platform leverages both multivalency and multi-specificity to generate highly efficacious antibodies with superior potency compared to traditional antibody platforms. These Multabodies are designed to have 24 binding sites, claiming to have a stronger and more secure hold on targets compared to conventional antibodies with only two binding sites, allowing Multabodies to potentially address targets that traditional antibodies cannot effectively engage.&nbsp;Radiant's technology aims to deliver a new class of biologics that can tackle complex, heterogeneous diseases such as cancer, autoimmune conditions, and infectious diseases. The company's lead clinical candidate is 4-1BB, which was advancing toward clinical trials as of September 2024. Radiant was also developing treatments for HIV, leveraging the Multabody platform's ability to potentially destroy latent viral stores and eliminate circulating viral particles.&nbsp;&nbsp;Key customers and partnershipsAs of October 2024, Radiant Biotherapeutics was developing a pipeline of infectious disease medicines in collaboration with multiple pharmaceutical companies, including the Lab of Jean-Philippe Julien, GSK, and Regeneron. As of April 2023, the company had entered development partnerships with two undisclosed pharmaceutical companies.&nbsp;

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

<div>
 
 Biotechnology firm Radiant Biotherapeutics has successfully garnered USD 35 million in a Series A funding round. The round was co-led by the Bill &amp; Melinda Gates Foundation and Amplitude Ventures, and received contributions from BDC Capital, abrdn, FACIT, Alexandria Venture Investments, and Toronto Innovation Acceleration Partners (TIAP).
 These funds are projected for use in advancing Radiant's chief immuno-oncology clinical candidate that targets 4-1BB (CD137) toward rigorous clinical trials.&nbsp;
 As a biotechnology firm, Radiant Biotherapeutics has its primary focus on various fields such as oncology, inflammation, immunology, and infectious diseases, including HIV. The Multabody platform of the company, based on its proprietary technology, utilizes multivalency and multi-specificity to manufacture antibodies that are significantly potent surpassing the capabilities of traditional antibody approaches. Radiant’s premier immuno-oncology candidate, labelled as 4-1BB, is making considerable progress toward clinical trials.
 
</div>

Radiant Biotherapeutics

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless